Neoprobe, Cardinal Health ink terms for Lymphoseek distribution:
This article was originally published in Clinica
Executive Summary
Manufacturer of oncology and cardiovascular products Neoprobe has signed a non-binding term sheet with Cardinal Health for the exclusive US marketing and distribution rights to its Lymphoseek radioactive lymphatic mapping targeting agent. Cardinal Health, headquartered in Dublin, Ohio, will provide Neoprobe with a distribution network of more than 150 nuclear pharmacies, and its wholesale distribution operations to in-hospital nuclear pharmacies. Neoprobe, also located in Dublin, Ohio, is developing Lymphoseek for use with hand-held gamma detection devices, and is preparing to submit a phase III multicenter clinical trial to the FDA.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.